Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Radionuclide Drug Conjugates (RDC) | 1 |
Small molecule drug | 1 |
Exosomes | 1 |
Radiopharmaceuticals and diagnostic agent | 1 |
Top 5 Target | Count |
---|---|
FAP(Fibroblast activation protein alpha) | 1 |
Target |
Mechanism FAP modulators |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date21 Nov 2024 |
Sponsor / Collaborator |
Start Date21 Nov 2024 |
Sponsor / Collaborator |
Start Date06 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Limbal Stem Cell Derived Exosomes Eye Drop | Dry Eye Syndromes More | Phase 1 |
177Lu-FAPI ( FAP ) | Metastatic breast cancer More | Phase 1 |
4-MU | Reperfusion Injury More | Preclinical |
KMTLL16E6/7 ( E6 x HPV E7 ) | Uterine Cervical Dysplasia More | Pending |